NURS 180 | Pharmacology | Week 2 Advanced Quiz | 2026 Update
WCU
1. A patient with hypoalbuminemia is prescribed a highly protein-bound
medication. Which clinical outcome should the nurse prioritize monitoring?
A. Decreased drug effectiveness due to rapid excretion.
B. Increased risk of drug toxicity due to higher levels of free drug.
C. Reduced absorption in the gastrointestinal tract.
D. Increased hepatic metabolism of the medication.
Answer: B
Rationale: Highly protein-bound drugs require albumin to transport them. In
hypoalbuminemia, there are fewer binding sites, leading to an increase in ‘free’ (active)
drug levels in the bloodstream, which increases the risk of toxicity.
2. Which process of pharmacokinetics is most directly affected by the ‘first-pass
effect’?
A. Metabolism
B. Excretion
C. Absorption
D. Distribution
Answer: A
Rationale: The first-pass effect occurs when a drug is metabolized by the liver immediately
after absorption from the GI tract and before it reaches systemic circulation, significantly
reducing its bioavailability.
,3. A drug has a half-life of 4 hours. If 1000 mg is administered at 12:00 PM, what
concentration remains in the body at 8:00 PM?
A. 500 mg
B. 250 mg
C. 125 mg
D. 62.5 mg
Answer: B
Rationale: After 4 hours (4 PM), 500 mg remains. After another 4 hours (8 PM), half of that
(250 mg) remains.
4. Which statement best describes the function of an ‘Antagonist’ drug?
A. It binds to a receptor and triggers a maximum therapeutic response.
B. It prevents receptor activation by endogenous compounds or other drugs.
C. It enhances the natural biochemical process of the cell.
D. It acts as a catalyst to speed up enzymatic reactions.
Answer: B
Rationale: Antagonists bind to receptors but do not activate them; instead, they block the
receptor from being activated by agonists or natural substances.
5. When assessing a patient’s renal function for drug clearance, which
laboratory value is the most accurate indicator?
A. Glomerular Filtration Rate (GFR)
B. Serum Potassium
C. Blood Urea Nitrogen (BUN)
D. Urine Specific Gravity
Answer: A
Rationale: GFR (or Creatinine Clearance) is the most reliable indicator of renal function
and the kidney’s ability to excrete drugs, compared to BUN which can be affected by
hydration and protein intake.
, 6. A drug with a ‘Narrow Therapeutic Index’ implies that:
A. The drug is very safe and requires no monitoring.
B. The difference between a lethal dose and a therapeutic dose is small.
C. The drug must be administered via the IV route only.
D. The drug has no potential for addiction.
Answer: B
Rationale: A narrow therapeutic index means there is a very small margin between the
effective dose and the toxic/lethal dose, necessitating close blood level monitoring.
7. Which phase of clinical drug trials involves testing the drug on a large number
of patients (1,000–3,000) to determine its safety and efficacy compared to
standard treatments?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: C
Rationale: Phase III trials use large patient populations to establish efficacy, monitor side
effects, and compare the drug to existing treatments before FDA approval.
8. Pharmacogenomics is the study of how:
A. Drugs affect the environment.
B. The body distributes drugs to various organs.
C. Drugs are manufactured in a laboratory setting.
D. Genetic variations affect an individual’s response to drugs.
Answer: D
Rationale: Pharmacogenomics focuses on how an individual’s genetic makeup influences
their response to specific medications, allowing for ‘personalized medicine’.
WCU
1. A patient with hypoalbuminemia is prescribed a highly protein-bound
medication. Which clinical outcome should the nurse prioritize monitoring?
A. Decreased drug effectiveness due to rapid excretion.
B. Increased risk of drug toxicity due to higher levels of free drug.
C. Reduced absorption in the gastrointestinal tract.
D. Increased hepatic metabolism of the medication.
Answer: B
Rationale: Highly protein-bound drugs require albumin to transport them. In
hypoalbuminemia, there are fewer binding sites, leading to an increase in ‘free’ (active)
drug levels in the bloodstream, which increases the risk of toxicity.
2. Which process of pharmacokinetics is most directly affected by the ‘first-pass
effect’?
A. Metabolism
B. Excretion
C. Absorption
D. Distribution
Answer: A
Rationale: The first-pass effect occurs when a drug is metabolized by the liver immediately
after absorption from the GI tract and before it reaches systemic circulation, significantly
reducing its bioavailability.
,3. A drug has a half-life of 4 hours. If 1000 mg is administered at 12:00 PM, what
concentration remains in the body at 8:00 PM?
A. 500 mg
B. 250 mg
C. 125 mg
D. 62.5 mg
Answer: B
Rationale: After 4 hours (4 PM), 500 mg remains. After another 4 hours (8 PM), half of that
(250 mg) remains.
4. Which statement best describes the function of an ‘Antagonist’ drug?
A. It binds to a receptor and triggers a maximum therapeutic response.
B. It prevents receptor activation by endogenous compounds or other drugs.
C. It enhances the natural biochemical process of the cell.
D. It acts as a catalyst to speed up enzymatic reactions.
Answer: B
Rationale: Antagonists bind to receptors but do not activate them; instead, they block the
receptor from being activated by agonists or natural substances.
5. When assessing a patient’s renal function for drug clearance, which
laboratory value is the most accurate indicator?
A. Glomerular Filtration Rate (GFR)
B. Serum Potassium
C. Blood Urea Nitrogen (BUN)
D. Urine Specific Gravity
Answer: A
Rationale: GFR (or Creatinine Clearance) is the most reliable indicator of renal function
and the kidney’s ability to excrete drugs, compared to BUN which can be affected by
hydration and protein intake.
, 6. A drug with a ‘Narrow Therapeutic Index’ implies that:
A. The drug is very safe and requires no monitoring.
B. The difference between a lethal dose and a therapeutic dose is small.
C. The drug must be administered via the IV route only.
D. The drug has no potential for addiction.
Answer: B
Rationale: A narrow therapeutic index means there is a very small margin between the
effective dose and the toxic/lethal dose, necessitating close blood level monitoring.
7. Which phase of clinical drug trials involves testing the drug on a large number
of patients (1,000–3,000) to determine its safety and efficacy compared to
standard treatments?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Answer: C
Rationale: Phase III trials use large patient populations to establish efficacy, monitor side
effects, and compare the drug to existing treatments before FDA approval.
8. Pharmacogenomics is the study of how:
A. Drugs affect the environment.
B. The body distributes drugs to various organs.
C. Drugs are manufactured in a laboratory setting.
D. Genetic variations affect an individual’s response to drugs.
Answer: D
Rationale: Pharmacogenomics focuses on how an individual’s genetic makeup influences
their response to specific medications, allowing for ‘personalized medicine’.
